摘要
根据专利组合分析评价体系,对2016到2022年医药制造业188家上市公司进行动态竞争地位研究。发现医药制造业各公司有加大专利研发的趋势,但差距仍较大;千金药业、东阿阿胶等实现了从潜力者到领导者的蜕变,恒瑞医药、康缘药业等实现了从活跃者到领导者的蜕变,说明要想在技术方面占有领导地位,公司可以先提升专利质量,成为潜力者后再逐步增加专利数量;也可以先增加专利数量,成为活跃者后再逐步提升专利质量。
According to the patent portfolio analysis and evaluation system,the dynamic competitive position of 188 listed companies in the pharmaceutical manufacturing industry from 2016 to 2022 was studied.It is found that the pharmaceutical manufacturing companies have the trend of increasing patent R&D,but the gap is still large;Qianjin pharmaceutical and Dong’e E-Jiao have transformed from potential person to leader,while Hengrui pharmaceutical and Kangyuan pharmaceutical have transformed from active person to leader,indicating that in order to occupy a leading position in technology,the company can first improve the quality of patents to become potential person,and then gradually increase the number of patents;the company can also increase the number of patents first to become active,and then gradually improve the quality of patents.
作者
李佳航
王蕾
王丽
鲍新中
LI Jiahang;WANG Lei;WANG Li;BAO Xinzhong(Management College,Beijing Union University,Beijing 100101)
出处
《中国发明与专利》
2023年第3期11-21,共11页
China Invention & Patent
基金
北京市社会科学基金重大项目“北京市高精尖产业知识产权证券化模式与机制研究”(项目编号:20ZDA03)。
关键词
专利组合
技术竞争地位
医药制造业
系统聚类
动态演化
patent portfolio
technology competitive position
pharmaceutical manufacturing
systematic clustering
dynamic evolution
